Mounjaro
UK · InjectionType 2 diabetes and weight management
FDA APPROVED COMPARATOR
Tirzepatide
A critical comparator showing how a multi receptor peptide can progress across diabetes, weight management, cardiovascular prevention and primary care pathways.
FDA STATUS
FDA approved in specific products and indications, including Mounjaro to reduce major adverse cardiovascular event risk in adults with type 2 diabetes at high cardiovascular risk
EVIDENCE MATURITY
Authorised medicine with pivotal obesity, diabetes and cardiovascular outcomes evidence
PROFESSIONAL RELEVANCE
Track NHS implementation, capacity, access criteria and real world outcomes. The US cardiovascular indication does not change UK authorisation or NHS access.
Product, formulation and indication
Mounjaro
US · InjectionType 2 diabetes and reduction of major cardiovascular event risk in adults at high cardiovascular risk
Zepbound
US · InjectionChronic weight management
Status history
Production baseline verification recorded.
Established FDA approved dual agonist
FDA cardiovascular risk reduction indication, approved 27 August 2026, added to the public record.
FDA approved dual agonist with a cardiovascular risk reduction indication
Future material changes will be appended with their previous status and source; they will not be silently overwritten.
Verify this record
Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.
- PRIMARYFDA · Mounjaro application overview
- PRIMARYFDA · Mounjaro revised prescribing information, 27 August 2026
- PRIMARYMHRA · product information verification route
- PRIMARYNICE · TA1026 recommendations
- PRIMARYNICE · TA1026 phased implementation
- PRIMARYClinicalTrials.gov · tirzepatide studies
- MARKET SIGNALMarket exposure classification method